About Index Trending news
Analyze
Pricing
BiondVax

BiondVax

Work at BiondVax? Add yourself to this profile

BiondVax

BiondVax (NASDAQ: $BVXV) is developing a Universal Flu Vaccine providing multi-season, multi-strain protection against seasonal & pandemic influenza.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding
Post-IPO debt
€20,000,000
Grant
$1,300,000
Employees

Team size

10+
Locations
HQ
Headquarters
€20,000,000 Post-IPO debt
The Times of Israel

BiondVax gets €20 million loan for universal flu vaccine

NoCamels

Israel’s BiondVax Moves Closer To Universal Flu Vaccine

Health Science
NoCamels

BiondVax's Flu Vaccine Trial Recruitment Complete

Health